Recent research shows that bendamustine monotherapy achieves high response rates and inhibits STAT3 in patients with high burden T-cell large granular lymphocytic leukemia. This study highlights the potential of bendamustine as an effective treatment option for this rare leukemia.
bendamustine monotherapy induces high response rates and stat3 inhibition in high burden t cell large granular lymphocytic leukemia
Original title: “"Bendamustine monotherapy induces high response rates and STAT3 inhibition in high burden T-cell large granular lymphocytic leukemia".”